A diabetes drug may soon double as a treatment for liver disease. Dapagliflozin, an SGLT-2 inhibitor typically used for type 2 diabetes, significantly improved liver inflammation and scarring in patients with metabolic dysfunction-associated steatohepatitis (MASH) during a clinical trial in China. Participants on the drug saw better liver outcomes and fewer side effects than those on a placebo. Although more research is needed, especially in diverse populations, this finding hints at a transformative role for existing medications in tackling liver diseases.
from Top Health News -- ScienceDaily https://ift.tt/wkv36OY
Subscribe to:
Post Comments (Atom)
-
Three treaties between the US and Hong Kong were suspended, the latest move to pressure China. from Yahoo News - Latest News & Headl...
-
At least 22 people were killed and 171 others injured on Sunday when one of Taiwan’s newer, faster trains derailed on a curve along a popula...
-
Prosecutors in Mexico have opened an investigation into former president Enrique Peña Nieto, who is accused of taking bribes in one of Latin...
No comments:
Post a Comment